Akèy › Skleroz an milti relaps-remitan
Etid klinik pou Skleroz an milti relaps-remitan ap rekrite nan Etazini
18 etid pou Skleroz an milti relaps-remitan ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Ap rekriteFaz 3
Laj 18 a 55 · Tout sèks · Mizajou Sep 16, 2026 · NCT04047628Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Sep 15, 2026 · NCT05958381Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Sep 10, 2026 · NCT06408259The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Ap rekrite
Laj 22 a 60 · Tout sèks · Mizajou Sep 2, 2026 · NCT06796504Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
Ap rekriteEtid obsèvasyon
Laj 40 a 70 · Tout sèks · Mizajou Aug 11, 2026 · NCT07758270Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT06864936Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Ap rekriteFaz 1/2
Laj 18 a 55 · Tout sèks · Mizajou Jul 2, 2026 · NCT05359653Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
Ap rekrite
Laj 45 a 89 · Tout sèks · Mizajou Jun 17, 2026 · NCT06919900Intermittent Hypoxia in Persons With Multiple Sclerosis
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Mar 20, 2026 · NCT06276634Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Mar 17, 2026 · NCT07225361Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
Ap rekrite
Laj 18 a 100 · Tout sèks · Mizajou Mar 6, 2026 · NCT07376772Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Feb 23, 2026 · NCT06390930Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Ap rekriteFaz 1 bonè
Laj 18 a 55 · Tout sèks · Mizajou Feb 9, 2026 · NCT06629428Home Based Functional Balance Intervention for Multiple Sclerosis
Ap rekrite
Laj 40 a 90 · Tout sèks · Mizajou Jan 21, 2026 · NCT07355387"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 31, 2025 · NCT07222618Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Ap rekrite
Laj 22 a 75 · Tout sèks · Mizajou Sep 24, 2025 · NCT05964829MS-ResearchBiomarkerS
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2024 · NCT05204459Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Ap rekriteEtid obsèvasyon
Laj 18 a 60 · Tout sèks · Mizajou Jun 6, 2022 · NCT04458688Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.